![Amgen Amgen](https://static.packgene.com/wp-content/uploads/2023/10/Amgen.jpg)
Dublin’s High Court was the final hurdle for the deal, as Horizon is based in Ireland, with most of its team in Chicago. On Thursday, the court gave its stamp of approval. The approving judge was satisfied that all criteria had been met for the takeover and there were no objections to the proposal, with 99.89% of shareholders voting in favor of the buy.
The biggest obstacle to the deal came from the FTC. However, in September 2023, the agency gave clearance to Amgen to proceed with the acquisition—but with strings. Under a consent order agreement, Amgen is prohibited from bundling any of its products with Horizon’s Tepezza or Krystexxa, which the FTC contends would stifle competition.
Amgen denied the claims and stated the objective of the acquisition was to expand its rare disease portfolio. To assuage the FTC’s concerns, Amgen signed an agreement prohibiting it from bundling any of its products with Tepezza or Krystexxa.
The deal brings in seven products already approved in the U.S. along with a healthy pipeline of assets already in clinical trials. Demand for its key drugs—Tepezza, Krystexxa and Uplizna—increased second-quarter revenues for 2023 by 8% over the prior year to bring in $945 million, exceeding estimates. Tepezza is its biggest seller with $445.5 million in sales in the second quarter of this year.
Amgen’s Horizon acquisition is the biggest to close this year. Pfizer continues to duke it out with the FTC over its massive $43 billion buy of Seattle-based Seagen. In July 2023, Pfizer announced the commission had requested additional information on the acquisition, which would further delay the deal. The transaction is expected to close by the end of the year, or in early 2024, subject to regulatory approval. The companies have also sought approval from the European Commission.
This week, a coalition of pharma companies banded together to push back against the overhaul of antitrust guidelines. The 31-member group—which includes AbbVie, Amgen, Gilead, Merck and Novartis—is advocating for “pro-innovation” mergers and acquisitions in the pharma sector.
![GMP mRNA](https://static.packgene.com/wp-content/uploads/2023/07/13.jpg)
Check out our AAV CDMO service to expedite your gene therapy research
PackGene Biotech is a world-leading CRO and CDMO, excelling in AAV vectors, mRNA, plasmid DNA, and lentiviral vector solutions. Our comprehensive offerings span from vector design and construction to AAV, lentivirus, and mRNA services. With a sharp focus on early-stage drug discovery, preclinical development, and cell and gene therapy trials, we deliver cost-effective, dependable, and scalable production solutions. Leveraging our groundbreaking π-alpha 293 AAV high-yield platform, we amplify AAV production by up to 10-fold, yielding up to 1e+17vg per batch to meet diverse commercial and clinical project needs. Moreover, our tailored mRNA and LNP products and services cater to every stage of drug and vaccine development, from research to GMP production, providing a seamless, end-to-end solution.
Related News
Skyline Therapeutics Receives FDA Orphan Drug Designation for Gene Therapy for Retinitis Pigmentosa
BOSTON & SHANGHAI, September 2, 2024 – Skyline Therapeutics, a gene therapy company focused on innovative treatments for rare and severe diseases, announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) for SKG1108....
Novavax Receives Emergency Use Authorization for Updated Covid-19 Vaccine
Novavax has received emergency use authorization (EUA) from the U.S. Food and Drug Administration (FDA) for its updated Covid-19 vaccine, NVX-CoV2705, joining other vaccine manufacturers in addressing evolving virus variants. The EUA permits the use of Novavax's...
Turn Biotechnologies Reports Historic Skin Cell Rejuvenation Breakthroughs at ESDR this Week
Company will present data from its successful rejuvenation of fibroblasts and keratinocytes to influential gathering of international dermatologists MOUNTAIN VIEW, Calif., Sept. 4, 2024 /PRNewswire/ -- Turn Biotechnologies, a developer of novel mRNA medicines and...
H5 influenza vaccines: What needs to be done to reduce the risk of a pandemic
As the global threat of H5N1 influenza looms with outbreaks across species and continents including the U.S., three international vaccine and public health experts say it is time to fully resource and support a robust strategy to address this and future potential...
Related Services
![](https://static.packgene.com/wp-content/uploads/2023/01/9-1.png)
Plasmids GMP Services
Multiple scales & grade of solutions of various kind of plasmids suitable for multiple treatments in a fast and cost effective way.
READ MORE
![](https://static.packgene.com/wp-content/uploads/2023/01/10-2.png)
AAV GMP Services
Ranging from small-scale AAV production, to large-scale AAV cGMP manufacturing for animal studies.
READ MORE
![aav icon](https://static.packgene.com/wp-content/uploads/2023/01/9-1.png)
Technology Platforms
PackGene’s proprietary π-Alpha™ 293 AAV High-yield Platform increases AAV production by 3 to 8 times that of traditional platforms.
READ MORE